



WHO WE ARE AND WHAT WE DO

IHT is a technology-enabled wound care services company, specializing in the delivery of negative pressure wound therapy (NPWT) systems.

MISSION: Improve the quality of life for patients who suffer from wounds and decrease the cost to the healthcare system.

GOAL: Introduce integrated systems for treating wounds throughout the continuum of care, including NPWT and therapeutic dressing systems; devices capable of delivering oxygen and fluids to the wound bed; and systems for treatment and prevention of surgical site incisional infection.

STRATEGY: Aggregate FDA-approved wound care therapies and delivery systems; establish synergistic clinically-effective and cost-efficient wound care systems; and invest in evidence-based medicine to support best practices for the treatment of acute and chronic wounds.

EXECUTIVE MANAGEMENT

Albert Rodewald
Chairman and CEO

John E. Blount
Chief Operating Officer

Gary B. Ferguson, PhD
Chief Revenue Officer

Jack Fisher, MD
Chief Medical Officer

Hans Seezen
Chief Financial Officer

HEALTHCARE OPPORTUNITY

The U.S. human wound market is approaching \$25B. The U.S. represents the largest and fastest growing market with over \$7.5B in annual purchase of wound care products, inclusive of \$1.5B for NPWT. The primary drivers of chronic wound management are:

- Diabetes and Cardiovascular Disease
- Obesity
- The Aging Population
- Hospital Acquired Infections (HAIs)

In the U.S. alone, there are 7 million chronic wounds treated annually, with a projected annual increase of 6%. NPWT is projected to increase at a rate of 10.3% year over year.

The Centers for Medicare and Medicaid Services (CMS) has proposed changing wound care reimbursement from the current fee-for-service model, in which treating physicians bill the government based on the number of procedures, to a pay-for-performance model in which reimbursement is fixed for a given diagnosis. Discussions are underway to bundle all treatment reimbursement within one episode of care. By 2017, the penalties associated with value-based purchasing (2%), hospital acquired conditions (1%) and excessive readmissions (3%) will be fully realized. These changes will dramatically alter the wound care market by shifting market share away from products with little demonstrated therapeutic benefit, to those with more cost-effective solutions.


NPWT has been demonstrated to accelerate wound healing, especially in the treatment of diabetes-associated chronic wounds. Where wound care providers encounter problems is when traditional NPWT therapy is inadequate. The cost of treatment doubles when wounds become infected and rises to more than \$100,000 when amputation becomes necessary, dramatically increasing mortality rates. Adoption of wound care therapy that has greater efficacy will decrease the cost of care and the ensuing incidence of amputation and death.

WHAT IS THE PROBLEM IHT IS SOLVING


- No comparative product research or proof of value
- No alternatives to traditional foam-based NPWT
- Pricing models are not aligned with incentive for rapid healing
- Elimination of biofilm in the wound and in the prevention of surgical infection
- Excessive bacterial burden contributing to chronic wounds
- An epidemic rise in antibiotic resistance

A QUICK LOOK AT THE MARKET


OBESITY IS A MAJOR FACTOR IN THE DIABETES EPIDEMIC



AN AGING POPULATION



ANNUAL BURDEN OF WOUND CARE



IHT's NPWT Products

With IHT's proprietary NPWT Dressing System, treating chronic wounds is our three-step process.

STEP 1 ERADICATE BIOFILM

PhaseOne®

- Kills on contact
- Non-toxic
- No resistance
- Neutralizes toxins

STEP 2 REMOVE PATHOGENS

Cutimed® Sorbact®

- Non-adherent
- Sequesters toxins
- Decreases pain medication need

STEP 3 NEGATIVE PRESSURE

NewEra™ Pumps

- Removes exudate
- Contracts wound
- Increases circulation